BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22087835)

  • 1. The emerging role of large immunophilin FK506 binding protein 51 in cancer.
    Romano S; Sorrentino A; Di Pace AL; Nappo G; Mercogliano C; Romano MF
    Curr Med Chem; 2011; 18(35):5424-9. PubMed ID: 22087835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK506 binding proteins as targets in anticancer therapy.
    Romano S; Di Pace A; Sorrentino A; Bisogni R; Sivero L; Romano MF
    Anticancer Agents Med Chem; 2010 Nov; 10(9):651-6. PubMed ID: 21182472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma.
    Romano S; Xiao Y; Nakaya M; D'Angelillo A; Chang M; Jin J; Hausch F; Masullo M; Feng X; Romano MF; Sun SC
    Nucleic Acids Res; 2015 Aug; 43(14):6983-93. PubMed ID: 26101251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells.
    Romano S; D'Angelillo A; Pacelli R; Staibano S; De Luna E; Bisogni R; Eskelinen EL; Mascolo M; Calì G; Arra C; Romano MF
    Cell Death Differ; 2010 Jan; 17(1):145-57. PubMed ID: 19696786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.
    Daudt DR; Yorio T
    Mol Vis; 2011; 17():1172-81. PubMed ID: 21617754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin.
    Li TK; Baksh S; Cristillo AD; Bierer BE
    J Cell Biochem; 2002; 84(3):460-71. PubMed ID: 11813252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Aspects of FKBP51 that Enable Melanoma Dissemination.
    D'Angelillo A; Staibano S; Russo M; Romano MF; Romano S
    Curr Mol Pharmacol; 2015; 9(2):141-7. PubMed ID: 25986563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential.
    Romano S; Staibano S; Greco A; Brunetti A; Nappo G; Ilardi G; Martinelli R; Sorrentino A; Di Pace A; Mascolo M; Bisogni R; Scalvenzi M; Alfano B; Romano MF
    Cell Death Dis; 2013 Apr; 4(4):e578. PubMed ID: 23559012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition.
    Baughman G; Wiederrecht GJ; Campbell NF; Martin MM; Bourgeois S
    Mol Cell Biol; 1995 Aug; 15(8):4395-402. PubMed ID: 7542743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FKBP51 and the NF-κB regulatory pathway in cancer.
    Romano S; Mallardo M; Romano MF
    Curr Opin Pharmacol; 2011 Aug; 11(4):288-93. PubMed ID: 21565553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKBP51 regulation of AKT/protein kinase B phosphorylation.
    Wang L
    Curr Opin Pharmacol; 2011 Aug; 11(4):360-4. PubMed ID: 21498116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.
    Annett S; Moore G; Robson T
    Pharmacol Ther; 2020 Nov; 215():107623. PubMed ID: 32622856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells.
    Romano MF; Avellino R; Petrella A; Bisogni R; Romano S; Venuta S
    Eur J Cancer; 2004 Dec; 40(18):2829-36. PubMed ID: 15571967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FK506-binding protein 51 (FKBP51) in Mycosis fungoides.
    Mascolo M; Romano MF; Ilardi G; Romano S; Baldo A; Scalvenzi M; Argenziano G; Merolla F; Russo D; Varricchio S; Pagliuca F; Russo M; Ciancia G; De Rosa G; Staibano S
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):735-744. PubMed ID: 28977697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
    Pei H; Li L; Fridley BL; Jenkins GD; Kalari KR; Lingle W; Petersen G; Lou Z; Wang L
    Cancer Cell; 2009 Sep; 16(3):259-66. PubMed ID: 19732725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis.
    Giordano A; Avellino R; Ferraro P; Romano S; Corcione N; Romano MF
    Am J Physiol Heart Circ Physiol; 2006 Jun; 290(6):H2459-65. PubMed ID: 16428340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90.
    Bracher A; Kozany C; Thost AK; Hausch F
    Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):549-59. PubMed ID: 21636895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large FK506-binding proteins shape the pharmacology of rapamycin.
    März AM; Fabian AK; Kozany C; Bracher A; Hausch F
    Mol Cell Biol; 2013 Apr; 33(7):1357-67. PubMed ID: 23358420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding.
    Denny WB; Valentine DL; Reynolds PD; Smith DF; Scammell JG
    Endocrinology; 2000 Nov; 141(11):4107-13. PubMed ID: 11089542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of FKBP51 in human cancers.
    Staibano S; Mascolo M; Ilardi G; Siano M; De Rosa G
    Curr Opin Pharmacol; 2011 Aug; 11(4):338-47. PubMed ID: 21530399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.